An ancient spice has attracted serious cardiovascular research, but its promise should not be confused with a replacement for clinically proven treatment
Cardamom carries its presence quietly. Open the green pod, and it releases a fragrance that is floral, warm and almost citrus-like, yet powerful enough to transform tea, rice, stews, pastries and traditional preparations. For centuries, it has travelled through kitchens, markets, religious traditions and long-distance trading networks as both a flavouring and a valued botanical product. Its modern health story centres on the possibility that cardamom may influence blood pressure, inflammation and oxidative stress. That possibility has since been transformed into a much stronger claim: that cardamom lowers blood pressure better than medication and has none of the side effects associated with pharmaceutical treatment. The more credible story is more valuable. Cardamom has produced promising early findings, but those findings do not establish that the spice can outperform prescribed treatment or replace medical care.
The biblical connection also requires precision. Song of Solomon 4:14 describes a garden containing nard, saffron, calamus, cinnamon, frankincense, myrrh, aloes and other fine spices. Cardamom is not explicitly named in the standard translations of that verse. Ancient spice names can sometimes be interpreted differently across languages and historical traditions, but cardamom’s presence in Solomon’s garden should not be presented as an established biblical fact. Its real history is already remarkable. Cardamom has long been associated with South Asian, Middle Eastern and East African food and trade cultures, where its distinctive aroma, rarity and portability made it a prized commodity. Its importance does not depend on placing it in a verse where the evidence is uncertain. Its place in ancient commerce, traditional knowledge and global cuisine is strong enough on its own.
Cardamom is also not one completely uniform ingredient. Green cardamom, commonly identified as Elettaria cardamomum, differs from black or greater cardamom, which belongs to another botanical group and carries a darker, smokier profile. Green cardamom is the variety most often discussed in the blood-pressure research cited in popular health content. Its seeds contain volatile oils and plant compounds such as 1,8-cineole and terpinyl acetate, alongside other constituents that contribute to its aroma and possible biological activity. The concentration of these compounds can change according to species, cultivation, harvest, storage and preparation. A whole pod used in cooking cannot automatically be treated as equivalent to a concentrated powder, extract or supplement. The identity of the plant, the part used and the amount administered all matter when traditional use is translated into scientific evidence.
The blood-pressure claim is connected to a small human study published in 2009 by Verma, Jain and Katewa. The researchers gave three grams of cardamom powder daily for 12 weeks to 20 newly diagnosed individuals with stage-one hypertension. They reported significant reductions in systolic, diastolic and mean blood pressure, alongside changes in antioxidant status and fibrinolytic activity. This was an important early signal, but the design places clear limits on what can be concluded. The study involved a very small group and did not establish that cardamom was superior to a blood-pressure medicine. It also did not provide the same level of evidence as a large, randomised, controlled clinical trial. A result observed in 20 people cannot be converted into a universal promise for every person with hypertension. It can justify further research, but it cannot by itself become a prescription.
The broader evidence is more restrained. A systematic review and meta-analysis published in Phytotherapy Research examined eight reports involving 595 participants. It found that green-cardamom supplementation was associated with a modest reduction in diastolic blood pressure, while the pooled evidence did not show a statistically significant effect on systolic blood pressure. The authors noted that the available trials were few, relatively small and in need of larger studies with longer follow-up. This is important because the image’s most striking claim concerns a dramatic reduction in systolic pressure. The evidence does not support presenting a 14-point reduction as a dependable effect for the general population. Cardamom may have a role in research into supportive dietary strategies, but its average effect, the people most likely to benefit and the most appropriate preparation remain unsettled questions.
Researchers have proposed several explanations for cardamom’s possible cardiovascular activity. Its volatile oils and other phytochemicals may influence oxidative stress, inflammatory pathways, vascular function and the behaviour of the endothelium, the inner lining of blood vessels. Laboratory and animal studies have suggested that some cardamom compounds may affect processes linked to blood-vessel relaxation and metabolic health. These mechanisms are biologically plausible, but plausibility is not the same as a demonstrated clinical outcome. A compound can change a biological marker without reducing strokes, heart attacks, kidney disease or premature death. The important question is not only whether cardamom affects a pathway. It is whether a consistent, safe and measurable improvement occurs in real patients over time.
There is no reliable evidence that cardamom lowers blood pressure better than prescribed medication. The studies available have not established a head-to-head advantage over standard antihypertensive treatment, and cardamom has not been shown to provide the same long-term protection against cardiovascular events. The World Health Organization’s hypertension guidance is based on confirmed diagnosis, cardiovascular risk, treatment targets, follow-up and medicines selected according to the patient’s condition. Lifestyle changes and healthy diets are important, but many people with hypertension still require medication. The fact that a 2009 cardamom study reported no side effects among its participants does not prove that cardamom has “zero pharmaceutical side effects” or that it is safer than every medicine. It simply describes what occurred within a small study over a limited period.
The practical distinction is between cardamom used as food and cardamom used as a concentrated intervention. A normal amount added to tea or cooking contributes flavour and small quantities of naturally occurring compounds within a broader diet. A supplement may deliver a much higher exposure, particularly when it contains concentrated powder or extract. The risks and effects can therefore be different. People with high blood pressure should have it measured properly, monitor it consistently and discuss treatment decisions with a qualified health professional. They should not stop prescribed medication because a social-media graphic attributes a dramatic effect to a spice. Hypertension can damage blood vessels, the heart, brain and kidneys while producing few noticeable symptoms. Feeling well after using a herb is not evidence that blood pressure has reached a safe level.
For Africa, cardamom offers an opportunity that extends beyond household wellness claims. The spice sits within a botanical value chain involving farmers, traders, processors, food manufacturers, exporters, laboratories and researchers. Where cultivation is commercially viable, producers can capture more value through quality drying, grading, packaging, grinding, traceability and the development of standardised food or botanical ingredients. Research institutions can examine local varieties, document their chemical profiles and test possible applications in nutrition, food preservation, cosmetics and pharmaceutical development. The opportunity is not to sell cardamom as a miracle cure. It is to build the knowledge, standards and processing capacity that allow a plant product to enter higher-value markets safely and credibly.
Finance is part of that transition. Small producers need predictable buyers, working capital and equipment. Processors need quality-control systems and access to formal markets. Researchers need sustained investment to move beyond small preliminary studies. Digital financial services can support traceable payments, supply-chain records, inventory management and market access, helping connect small agricultural enterprises to more dependable commercial opportunities. But finance becomes truly transformative only when it is connected to standards, skills, infrastructure and trust. Cardamom’s future is therefore not simply about selling more spice. It is about helping communities participate in a value chain where quality is measurable, information is reliable and economic returns are distributed more broadly.
Cardamom is not a miracle substitute for blood-pressure medicine, but neither is it a plant without promise. Early research suggests that it may influence blood-pressure and inflammatory markers, while its culinary and cultural value is already well established. The evidence, however, remains too limited to support claims that it lowers blood pressure better than medication or carries no side effects. Its real power lies in the questions it opens: how can traditional plants be studied without exaggeration, how can promising compounds be developed safely and how can African producers capture more value from botanical resources? Cardamom does not need a miracle story to matter. Its future will be determined by the quality of the evidence, the safety of the products and the systems built around it.
Resources
- Song of Solomon 4:14, Bible Gateway
- Verma, Jain and Katewa (2009), “Blood Pressure Lowering, Fibrinolysis Enhancing and Antioxidant Activities of Cardamom”
- Izadi et al. (2023), systematic review and meta-analysis of green cardamom and blood pressure
- Yahyazadeh et al. (2021), review of cardamom supplementation and blood pressure
- World Health Organization, Guideline for the Pharmacological Treatment of Hypertension
- American Heart Association, managing high blood pressure and prescribed medication
